ArticleHarm reduction journal2024
Exploring the role of community pharmacies as a harm reduction environment for anabolic-androgenic steroid consumers: triangulating the perspectives of consumers and pharmacists.
Article in Harm reduction journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Making 'safer injecting' matter for people who inject image and performance enhancing drugs.Health (London, England : 1997) · 2026Article
- Public Knowledge and Perceptions of Fentanyl Test Strips: A National Cross-Sectional Survey Informed by the Health Belief Model.Healthcare (Basel, Switzerland) · 2026Article
- Confidence in Managing Use and Minimising Harm as Mediators of Quality of Life among Anabolic-Androgenic Steroid Consumers in Alcohol and Other Drug Treatment Settings.European addiction research · 2026Article
- Exploring the perspective of Malaysian Community Pharmacists on Sports Pharmacy Services: A qualitative study.Journal of public health research · 2026Article
- Co-producing a peer-led health conversation tool for the health services workforce to facilitate safer use of anabolic-androgenic steroids.Harm reduction journal · 2025Article
- Creating Safer Injecting Practices Through Community-Led Harm Reduction: Lessons From People Who Use Steroids for the Alcohol and Other Drug Sector.Drug and alcohol review · 2025Article
- Looking for the Best Way to Come Off Steroids Safely? Exploring Post-Cycle Therapy, Cessation, and Recovery Discourse and Practice in Australian Steroid Consumer Forums.Drug and alcohol review · 2025Article
- Health and Performance Challenges in the Era of Human Enhancement: Insights from Sport Medicine Professionals.Sports medicine (Auckland, N.Z.) · 2025Article
- The world's first anabolic-androgenic steroid testing trial: A two-phase pilot combining chemical analysis, results dissemination and community feedback.Addiction (Abingdon, England) · 2025Article
- Steroid-Induced Cardiomyopathy: Insights From a Systematic Literature Review and a Case Report.Clinical case reports · 2025Article
- Community pharmacy's role in dispensing androgens and supporting harm reduction amid current policy dilemmas.Substance abuse treatment, prevention, and policy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile community pharmacies have been successful in providing harm reduction support for illicit substance consumers, little research has explored their role in addressing the needs of anabolic-androgenic steroid (AAS) consumers.
objectiveThis study aimed to triangulate the attitudes and experiences of AAS consumers and community pharmacist's regarding AAS harm reduction.
methodsSemi-structured interviews were conducted with AAS consumers (n = 8) and community pharmacists (n = 15) between December 2022 and August 2023 in Australia. Interview data were analysed using reflexive thematic analysis.
resultsWhile consumers emphasised easy access to pharmacies, particularly in urban areas, challenges were noted in rural regions. AAS consumers expressed a preference for community pharmacies, perceiving them as less confronting and a feasible avenue for accessing professional advice, highlighting the potential role of pharmacists in nurturing therapeutic alliances with AAS consumers. Similarly, pharmacists expressed receptivity to providing harm reduction information but acknowledged knowledge gaps, suggesting a need for tailored education programs to support AAS consumers effectively.
conclusionsCommunity pharmacies can be an important environment for AAS harm reduction. Strategies include utilising private spaces for open discussions with AAS consumers and enhancing pharmacists' understanding of AAS to foster trust and support. Further research is needed to address knowledge gaps and training needs for pharmacy staff, with the aim of creating a safer environment for AAS consumers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.